Bora Pharmaceuticals, a CDMO which specialises in immediate and modified release oral solids and packaging, hasappointed Lonnie Barish, MBA as VP of Business Development and Marketing.
Adding more than 25 years of pharmaceutical, biotech, and medical device experience to the team, Barish will offer local support to new and existing clients in North America whilst helping to boost the growth of Bora’s North American business.
Bobby Sheng, CEO at Bora Pharmaceuticals said: “We are truly honored to add Lonnie to our growing team in North America.”
“Lonnie has been a senior leader at some of the most dynamic contract service organisations in our industry," said Sheng. "He will contribute significant business development and commercial experience alongside a deep understanding of the needs of our pharmaceutical industry customers.”
Sheng added: “As more customers continue to outsource their most challenging oral solid drug products to us, there is a greater need than ever for our extended release and solvent processing capabilities. Lonnie will help us to meet this demand and ensure we are reaching those pharmaceutical companies that would benefit from our skilled team and services.”
Headquartered in Zhunan, Taiwan, Bora recently confirmed plans to acquire GSK’s Mississauga, Canada facility by the end of 2020. The deal, which will considerably increase Bora’s size, capacity, and capabilities to include semi solids and liquids, will see the company commit to retaining approximately 400 GSK staff and continue to produce GSK products for over 100 markets for a minimum of five years.
Barish, who has held leadership roles at Cytovance Biologics, WellSpring, Nuvisan and AAIPharma, is the first of a number of planned key appointments as the company looks to expand its business development team across the continent.
Barish said: “I was excited to become a member of the Bora team because of its people, its core values, and its commitment to supporting global business strategy for its customers. Its unique experience and commercial capabilities are hard to come by in our industry.”
Barish added: “Bora’s outstanding regulatory history with the FDA, MHRA, and TFDA coupled with its technical agility are key differentiators in its service offering. In particular, its expertise in spheronisation, bilayer tableting, and handling solvents are invaluable to the oral solids market. It’s great to be part of an ambitious team so committed to supporting its customers in the complex oral solids space.”
Across its two sites in Taiwan, Bora offers a broad range of technologies to its global customer-base from development to manufacturing, packaging, distribution, technical transfer, stability studies, and product life cycle management.
